Table 2.
Comparison of the result of moderation effect evaluation by subgroup analysis
| Subgroup by cancer type |
Adjusted HR* (95% CI) | Adjusted HR* (95% CI) | |||||
|---|---|---|---|---|---|---|---|
| DBIII | DBDII | Effect size |
DBIII | DBDII | Effect size |
||
| Breast cancer | In age < 50 | In age ≥ 50 | |||||
| Non-HT | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | |||
| AI-only | 1.31 (0.94–1.84) | 1.21 (0.85–1.71) | 0.04 | 0.89 (0.79–1.01) | 0.98 (0.88–1.08) | 0.05 | |
| TAM-only | 0.83 (0.69–1.01) | 0.93 (0.78–1.10) | 0.06 | 0.80 (0.68–0.94) | 0.78 (0.69–0.89) | 0.01 | |
| AI + TAM | 0.19 (0.01–3.03) | 0.27 (0.04–1.95) | 0.19 | 0.46 (0.23–0.92) | 0.98 (0.68–1.42) | 0.42 | |
| Prostate cancer | Localized stage | Regional stage | |||||
| Non-ADT | 1 (Reference) | 1 (Reference) | 1 (Reference) | 1 (Reference) | |||
| ADT | 2.27 (1.91–2.70) | 1.92 (1.70–2.17) | 0.09 | 1.80 (1.37–2.36) | 2.05 (1.67–2.52) | 0.07 | |
Abbreviations: ADT: androgen deprivation therapy; AI: aromatase inhibitors; CI: confidence interval; DB: data base; DII: directly identifiable information; III: indirectly identifiable information; HR: hazard ratio; HT: hormone therapy; III: indirectly identifiable information
*Adjusted HR was computed after all covariates excluding the treatment and subgroup variables